search
Back to results

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus (PATAC)

Primary Purpose

Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation

Status
Completed
Phase
Not Applicable
Locations
Belarus
Study Type
Interventional
Intervention
Tacrolimus
Sponsored by
Republican Scientific and Practical Center for Organ and Tissue Transplantation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Early Allograft Dysfunction focused on measuring Liver transplantation, Early allograft dysfunction, Ischemic reperfusion injury, Portal and arterial ex vivo HTK flush

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Donor:

age 15-65 years macrovesicular steatosis < 40% (macroscopy or biopsy) sodium <165 mmol/l ICU stay and ventilation < 11 days cold ischemia time < 13 hours AST < 200 U/l ALT < 200 U/l bilirubin < 50 μmol/l application of norepinephrine is allowed

  • Recipient age: 18-69

Exclusion Criteria:

Recipient:

  • live donor liver transplant
  • reduced and split grafts
  • multi organ failure

Sites / Locations

  • RSPC for organ and tissue transplantation, Minsk 9th clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Tacrolimus + HTK

HTK

Arm Description

During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.

During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.

Outcomes

Primary Outcome Measures

Early Allograft Dysfunction
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. Early allograft dysfunction will be assessed on the basis of highest levels of AST and ALT during 1-7 postoperative days.

Secondary Outcome Measures

Ischemic Reperfusion Injury of the Liver Allograft
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. A wedge resection of small (5x5mm) part of liver segment-III will be sampled at 2 hours after venous reperfusion. Rate of necrosis, inflammation, vascular thrombosis, cluster of differentiation (CD) 68 and High mobility group box 1 protein (HMGB1) staining will be assessed thereafter.
Inflammatory Response to Reperfusion
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. After unclamping portal vein but before unclamping the inferior vena cava and after venting of first 100 ml of blood a 5 ml sample of blood (code is "HV") from a tube inserted into caval suture line will be taken. Another 5 ml sample of blood (code is "C") will be taken by puncture of one of hepatic veins 20 min later. Samples (5 ml each) of peripheral blood will be taken on 1st and 3d postoperative day (POD). P-selectin, interleukin-6, interleukin-8, tumor necrosis factor alfa (TNF-a) and macrophage inflammatory protein 1 alpha (MIP-1a) will be determined in samples "HV" and "C". Interleukin-8, elastase, TNF-a and vascular endothelial growth factor (VEGF) will be determined in samples of 1st and 3d POD.
Postreperfusion Hyperfibrinolysis
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. Peripheral blood samples will be taken 15 min and 2 hours after portal reperfusion. Hyperfibrinolysis will be diagnosed by Thromboelastometry (ROTEM) if one or more following criteria are met: LI30<85% or ML>15% or LI60<85% or A10 in Extem is by 15% is less then A10 in Aptem.

Full Information

First Posted
April 6, 2013
Last Updated
December 31, 2016
Sponsor
Republican Scientific and Practical Center for Organ and Tissue Transplantation
search

1. Study Identification

Unique Protocol Identification Number
NCT01887171
Brief Title
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Acronym
PATAC
Official Title
A Randomized Study of Effect of Preimplantation Portal Vein and Hepatic Artery Liver Flushing With Tacrolimus on Ischemia-reperfusion Injury, Allograft Dysfunction and Liver Histology
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Republican Scientific and Practical Center for Organ and Tissue Transplantation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.
Detailed Description
Early allograft liver dysfunction remains a significant complication of cadaveric liver transplantation with resource consuming and costly treatment, increased risk of multiorgan failure and 6-months mortality. Ischemic reperfusion injury (IRI) is a main reason for early allograft liver dysfunction. Inflammatory response to brain death in donor can precipitate the extent of dysfunction after reperfusion in recipient (1). Clear inflammatory pathways in response to IRI have been reported to be associated with early allograft liver dysfunction (2,3). It was shown that ex vivo intraportal tacrolimus perfusion suppressed inflammation and immune response in the transplanted liver on a genome-wide basis (4). We hypothesize that Tacrolimus added to HTK solution given through intraportal and intraarterial back-table infusion is capable of reducing the degree of early allograft liver dysfunction, as assessed by incidence of postreperfusion hyperfibrinolysis, postoperative levels of AST,ALT, during 1-7 postoperative days as well as serum and histochemical markers of liver injury and inflammation compared to no intraportal and intraarterial back-table infusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation, Hyperfibrinolysis
Keywords
Liver transplantation, Early allograft dysfunction, Ischemic reperfusion injury, Portal and arterial ex vivo HTK flush

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
86 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tacrolimus + HTK
Arm Type
Experimental
Arm Description
During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
Arm Title
HTK
Arm Type
No Intervention
Arm Description
During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
Intervention Type
Drug
Intervention Name(s)
Tacrolimus
Other Intervention Name(s)
Tacrolimus, Astellas Pharma Europe, Custodiol, Dr. Franz Köhler Chemie GmBH
Intervention Description
1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
Primary Outcome Measure Information:
Title
Early Allograft Dysfunction
Description
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. Early allograft dysfunction will be assessed on the basis of highest levels of AST and ALT during 1-7 postoperative days.
Time Frame
1-7 postoperative days after liver transplant procedure
Secondary Outcome Measure Information:
Title
Ischemic Reperfusion Injury of the Liver Allograft
Description
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. A wedge resection of small (5x5mm) part of liver segment-III will be sampled at 2 hours after venous reperfusion. Rate of necrosis, inflammation, vascular thrombosis, cluster of differentiation (CD) 68 and High mobility group box 1 protein (HMGB1) staining will be assessed thereafter.
Time Frame
liver biopsy taken at 2 hours after portal reperfusion
Title
Inflammatory Response to Reperfusion
Description
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. After unclamping portal vein but before unclamping the inferior vena cava and after venting of first 100 ml of blood a 5 ml sample of blood (code is "HV") from a tube inserted into caval suture line will be taken. Another 5 ml sample of blood (code is "C") will be taken by puncture of one of hepatic veins 20 min later. Samples (5 ml each) of peripheral blood will be taken on 1st and 3d postoperative day (POD). P-selectin, interleukin-6, interleukin-8, tumor necrosis factor alfa (TNF-a) and macrophage inflammatory protein 1 alpha (MIP-1a) will be determined in samples "HV" and "C". Interleukin-8, elastase, TNF-a and vascular endothelial growth factor (VEGF) will be determined in samples of 1st and 3d POD.
Time Frame
0 and 20 min after portal reperfusion, 1 and 3 postoperative day
Title
Postreperfusion Hyperfibrinolysis
Description
Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion. Peripheral blood samples will be taken 15 min and 2 hours after portal reperfusion. Hyperfibrinolysis will be diagnosed by Thromboelastometry (ROTEM) if one or more following criteria are met: LI30<85% or ML>15% or LI60<85% or A10 in Extem is by 15% is less then A10 in Aptem.
Time Frame
15 min and 2 hours after portal reperfusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Donor: age 15-65 years macrovesicular steatosis < 40% (macroscopy or biopsy) sodium <165 mmol/l ICU stay and ventilation < 11 days cold ischemia time < 13 hours AST < 200 U/l ALT < 200 U/l bilirubin < 50 μmol/l application of norepinephrine is allowed Recipient age: 18-69 Exclusion Criteria: Recipient: live donor liver transplant reduced and split grafts multi organ failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aliaksei E Shcherba, PhD
Organizational Affiliation
RSPC for tissue and organ transplantation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Oleg O Rumo, MD PhD
Organizational Affiliation
RSPC for organ and tissue transplantation, Minsk 9th clinic
Official's Role
Study Chair
Facility Information:
Facility Name
RSPC for organ and tissue transplantation, Minsk 9th clinic
City
Minsk
ZIP/Postal Code
220116
Country
Belarus

12. IPD Sharing Statement

Citations:
PubMed Identifier
22006860
Citation
Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, Olthoff KM. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl. 2012 Feb;18(2):166-76. doi: 10.1002/lt.22451.
Results Reference
background
PubMed Identifier
12827549
Citation
Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003 Jul;9(7):651-63. doi: 10.1053/jlts.2003.50105.
Results Reference
background
PubMed Identifier
18825712
Citation
Ilmakunnas M, Tukiainen EM, Rouhiainen A, Rauvala H, Arola J, Nordin A, Makisalo H, Hockerstedt K, Isoniemi H. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008 Oct;14(10):1517-25. doi: 10.1002/lt.21573.
Results Reference
background
PubMed Identifier
21672049
Citation
Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Muhlbacher F, Oberbauer R, Bodingbauer M. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transpl Int. 2011 Sep;24(9):912-9. doi: 10.1111/j.1432-2277.2011.01284.x. Epub 2011 Jun 14.
Results Reference
background
PubMed Identifier
20677285
Citation
Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091.
Results Reference
background
Citation
Shcherba A.E., Minou A.F., Efimov D.J., Korotkov S.V., LebedzO.A., Dzyadzko A.M., Karitka A., Santotski E.O., Rummo O.O.//Influence of Back Table Portal And Arterial Flushing with HTK and Tacrolimus on the Incidence of Liver Graft Dysfunction. Materials of "Avantguardia in the HPB - surgery and Liver transplantation: When East meets West". Volume 61, June 2014, Supplement 1.- P. S13-14.
Results Reference
result
PubMed Identifier
25044812
Citation
Abstracts of the ILTS 20(th) Annual International Congress, June 3-7, 2014, London, United Kingdom. Liver Transpl. 2014 Jun;20 Suppl 1:S1-399. doi: 10.1002/lt.23901. No abstract available.
Results Reference
result
Links:
URL
http://journal.transpl.ru/vtio/article/view/561/488
Description
Related Info
URL
http://www.jtmr.ro/article/portal-and-arterial-flushing-with-htk-and-tacrolimus-can-attenuate-the-incidence-of-early-liver-allograft-dysfunction
Description
Related Info
Available IPD and Supporting Information:
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
http://journal.transpl.ru/vtio/article/view/561/488
Available IPD/Information Identifier
10.15825/1995-1191-2015-3-24
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
http://www.jtmr.ro/article/portal-and-arterial-flushing-with-htk-and-tacrolimus-can-attenuate-the-incidence-of-early-liver-allograft-dysfunction
Available IPD/Information Identifier
10.21614/jtmr-21-2-82

Learn more about this trial

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

We'll reach out to this number within 24 hrs